clinical trial · NCT04990427
CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)
Chronic Kidney DiseasesCLBS201
brief summary
CLBS201 will evaluate the safety, tolerability, and therapeutic effect in subjects with CKD and T2DM.
started
Jan 10, 2022
primary completion
Jan 26, 2023
completion
Jan 26, 2023
last updated
Oct 9, 2024
official title
A Phase 1 Open-Label, Proof-of-Concept Study to Evaluate the Safety and Efficacy of CLBS201 Autologous Peripheral Blood-Derived CD34+ Cells in Subjects with Chronic Kidney Disease and Type 2 Diabetes Mellitus
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol